AMPE Share Price | Ampio Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Ampio Pharmaceuticals, Inc. do?

Overview: Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for prevalent inflammatory conditions within the Pharmaceuticals & Biotechnology industry.Financial Snapshot: Most recent Net Profit: -2 Million (Quarterly Results - Dec 2023) Market cap: USD 0.00 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.14 Return on Equity: -265.51% Price to Book: 0.00Contact Details: Address: 373 Inverness Pkwy Ste 200, ENGLEWOOD CO: 80112-5898 Tel: 1 720 4376500 Website: http://ampiopharma.com/

Q: Is Ampio Pharmaceuticals, Inc. overvalued or undervalued?

As of 2 August 2016, the valuation grade for Ampio Pharmaceuticals, Inc. moved from risky to does not qualify. The company is currently considered overvalued given its financial metrics and performance. The price-to-book value stands at a mere 0.04, while the EV to EBITDA ratio is 0.40, indicating significant underperformance relative to its peers. Additionally, the return on capital employed (ROCE) is extraordinarily high at 951.80%, but this is misleading due to the negative return on equity (ROE) of -265.51%.In comparison to its peers, Ampio Pharmaceuticals, Inc. does not qualify with a P/E ratio of -0.0003, while Kinnate Biopharma, Inc. is rated fair with a P/E of -1.1313, and ADC Therapeutics SA is rated risky with a P/E of -2.1005. The stark contrast in valuation and performance metrics suggests that Ampio is not positioned favorably in the market. Furthermore, the company's stock has dramatically underperformed against the S&P 500, with a one-year return of -97.92% compared to the index's 10.26%, reinforcing the notion of overvaluation.

Q: Is Ampio Pharmaceuticals, Inc. technically bullish or bearish?

As of 26 August 2025, the technical trend for Ampio Pharmaceuticals, Inc. has changed from mildly bullish to mildly bearish. The current stance is mildly bearish, driven by a bearish RSI on both weekly and monthly time frames, along with a mildly bearish daily moving average. The weekly MACD remains mildly bullish, but the overall indicators suggest weakness. The company has a year-to-date return of 3.85%, underperforming the S&P 500's 12.22%, and has significantly negative returns over the longer term, indicating a challenging environment.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

Shareholding (Dec 2023)

FII

0.32%

Held by 16 FIIs

DII

89.52%

Held by 10 DIIs

Promoter

0.00%

How big is Ampio Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Ampio Pharmaceuticals, Inc. has a market capitalization of 0.00, categorizing it as a Micro Cap company, with net sales of 0.00 million and a net profit of -8.63 million over the latest four quarters. Shareholder's funds are 3.36 million, and total assets are 5.74 million.

View full answer

What does Ampio Pharmaceuticals, Inc. do?

22-Jun-2025

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing therapies for inflammatory conditions. As of December 2023, it has a market cap of $0 million and reported a net profit loss of $2 million.

View full answer

Who are in the management team of Ampio Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Ampio Pharmaceuticals, Inc. includes Mr. Michael Macaluso as Chairman and CEO, with Dr. David Bar-Or as a Director and Mr. Philip Coelho, Mr. Richard Giles, and Dr. David Stevens serving as Independent Directors.

View full answer

Is Ampio Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of August 2, 2016, Ampio Pharmaceuticals, Inc. is considered overvalued and does not qualify for a favorable valuation grade due to poor financial metrics, including a P/E ratio of -0.0003 and a one-year return of -97.92%, significantly underperforming against the S&P 500.

View full answer

Is Ampio Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of August 26, 2025, Ampio Pharmaceuticals, Inc. is in a mildly bearish trend due to negative RSI indicators and underperformance compared to the S&P 500, despite a mildly bullish weekly MACD.

View full answer

Compare Ampio Pharmaceuticals, Inc. with Similar Stocks

Adicet Bio, Inc.Xilio Therapeutics, Inc.Outlook Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 0 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.14

Return on Equity

-265.51%

Price to Book

0.09

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2023)

Net Profit:

-2 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.0%

6 Months

244.83%

1 Year

0.0%

2 Years

-99.44%

3 Years

-96.62%

4 Years

-99.99%

5 Years

-100.0%

Ampio Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

EBIT Growth (5y)

2.79%

EBIT to Interest (avg)

-17.07

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.14

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

23.61%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.04

EV to EBIT

0.39

EV to EBITDA

0.40

EV to Capital Employed

3.67

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

951.80%

ROE (Latest)

-265.51%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bullish

RSI

Bearish

Bollinger Bands

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Mildly Bullish

Dow Theory

No Trend

OBV

Mildly Bullish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 19 Schemes (10.16%)

Foreign Institutions

Held by 16 Foreign Institutions (0.32%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'23 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2023 is 4.55% vs 64.52% in Dec 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.20",
          "val2": "-2.30",
          "chgp": "4.35%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.40",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-2.10",
          "val2": "-2.20",
          "chgp": "4.55%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2023 is 47.24% vs 4.68% in Dec 2022",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'23",
        "Dec'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.30",
          "val2": "-18.30",
          "chgp": "49.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.30",
          "val2": "3.80",
          "chgp": "-92.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-8.60",
          "val2": "-16.30",
          "chgp": "47.24%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'23 - YoY

Dec'23

Dec'22

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-2.20

-2.30

4.35%

Interest

0.00

Exceptional Items

0.00

0.40

-100.00%

Consolidate Net Profit

-2.10

-2.20

4.55%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Consolidated Net Profit

YoY Growth in quarter ended Dec 2023 is 4.55% vs 64.52% in Dec 2022

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'23

Dec'23

Dec'22

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-9.30

-18.30

49.18%

Interest

0.00

Exceptional Items

0.30

3.80

-92.11%

Consolidate Net Profit

-8.60

-16.30

47.24%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2023 is 0.00% vs 0.00% in Dec 2022

Consolidated Net Profit

YoY Growth in year ended Dec 2023 is 47.24% vs 4.68% in Dec 2022

All Annual Results

Company CV

About Ampio Pharmaceuticals, Inc.

Ampio Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.

Company Coordinates

Company Details

373 Inverness Pkwy Ste 200 , ENGLEWOOD CO : 80112-5898

Tel: 1 720 4376500

http://ampiopharma.com/

Registrar Details

Ampio Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Ampio Pharmaceuticals, Inc.?

Watch in Real-Time

What does Ampio Pharmaceuticals, Inc. do?

Who are in the management team of Ampio Pharmaceuticals, Inc.?

Is Ampio Pharmaceuticals, Inc. overvalued or undervalued?

Is Ampio Pharmaceuticals, Inc. technically bullish or bearish?

Compare Ampio Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Dec 2023

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Dec'23 - YoY

Annual Results Snapshot (Consolidated) - Dec'23

About Ampio Pharmaceuticals, Inc.

Company Coordinates